Deep biotech encompasses a range of advanced technological areas, such as machine learning and AI, synthetic (engineering) biology, nanotechnologies, advanced materials and quantum computing that each have the ability to profoundly catalyse change in global issues such as waste, pollution, climate change and food security.
The BIA reported in 2025 on the emergence of Deep Biotech, which raised over £1bn between 2018 and 2024. Of the 91 companies listed by the BIA as working in this area and based in the south of England, CMS has advised 6 on IP matters, and others on, for example, regulatory matters. The European Patent Office has a deep tech company finder here
Multiple Deep Biotech companies are currently on CMS’ equIP Life Sciences programme, which fosters a community of similar companies and provides a discount on legal fees.
Our deep expertise in deepbiotechnology includes, for example, ML and quantum computing technologies as applied to biology, chemistry and the environment, advanced manufacturing in the area of cultured meats, carbon capture technologies such as direct carbon capture from atmospheric air.
